Filing Flows › Axsome Therapeutics (AXSM) › Guidance & outlook
Axsome Therapeutics (AXSM) guidance and outlook
Axsome Therapeutics' 10-Q filed Nov 2, 2026 makes 21 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 2, 2026
- Our commercial products are our primary sources of revenue and are expected to be key contributors to future revenue growth.
- As part of our ongoing research and development activities, we have and will continue to allocate significant resources to support the development of our product candidates.
- We plan to evaluate AXS-17 as a potential treatment for epilepsy.
- We plan to evaluate AXS-20 as a potential treatment for schizophrenia and Tourette syndrome.
- The revenue we have generated, and anticipate to continue to generate, from the commercial sales of AUVELITY, SUNOSI, and SYMBRAVO, is expected to be an important contributor to our progress toward profitability.
- Our accumulated deficit as of September 30, 2026 was $1,434.7 million, and we expect to incur significant expenses and continuing operating losses.
- We expect our expenses to increase in connection with our ongoing activities, as we continue the commercialization of our on-market products and the development and clinical trials of, and seek regulatory approval for, our current product candidates and any other product candidates that we develop or in-license and advance to clinical development.
- Further, we have incurred and will continue to incur additional costs associated with operating as a public company.
- We will need to generate significant revenue to achieve profitability, and we may never do so.
- We expect that AUVELITY, SUNOSI, and SYMBRAVO revenues are likely to fluctuate based on demand quarter to quarter.
- We will not generate revenue from other products unless and until we successfully develop, obtain regulatory approval of, and commercialize one of our current or future product candidates.
- We will receive a royalty percentage in the mid-twenties on net sales of the Licensed Products (as defined in the Pharmanovia License Agreement) in the Licensed Territory.
Axsome Therapeutics' latest quarter
Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.
Questions
What does Axsome Therapeutics expect?
Our commercial products are our primary sources of revenue and are expected to be key contributors to future revenue growth. As part of our ongoing research and development activities, we have and will continue to allocate significant resources to support the development of our product candidates. We plan to evaluate AXS-17 as a potential treatment for epilepsy.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.